共 129 条
[1]
Lehto M(2005)Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience Eur Heart J 26 350-356
[2]
Snapinn S(2005)Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET Eur Heart J 26 1303-1308
[3]
Dickstein K(2006)ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation
[4]
Swedberg K(1999)The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution Eur Heart J 20 748-754
[5]
Nieminen MS(2007)Antithrombotic treatment in atrial fibrillation Heart 93 39-44
[6]
Swedberg K(2006)Antithrombotic therapy for congestive heart failure Int J Clin Pract 60 36-47
[7]
Olsson LG(2009)Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop Circulation 119 606-618
[8]
Charlesworth A(1997)Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide Clin Cardiol 20 704-710
[9]
Cleland J(1999)Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group N Engl J Med 341 857-865
[10]
Hanrath P(2000)Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial Lancet 356 2052-2058